or
Nature Reviews Drug Discovery 19, 376-377 (2020)
doi: https://doi.org/10.1038/d41573-020-00093-1
Acknowledgements
CRI and IQVIA are immensely grateful to all the investigators and institutional research staff, including the Oncology Clinical Trials Project Managers at IQVIA, for providing their valuable time and insights for this publication. The authors also want to thank M. Aitken, Senior Vice President and Executive Director of the IQVIA Institute for Human Data Science; C. Chang, Chief Medical Officer and Regulatory Affairs, IQVIA China; E. Groves, Vice President, Strategic Drug Development IQVIA; and P. Fredette, Strategic Site Networks Director, Oncology IQVIA.
V.M.H.-L is a scientific advisor and has equity interest in Fx Biopharma. The other authors declare no competing interests.
